Introduction:

Primary Sclerosing Cholangitis (PSC) Market was valued at US$ 163.1 Million in 2024 and is projected to grow at a CAGR of 15.1% to reach US$ 586.8 Million by 2034.

Primary Sclerosing Cholangitis (PSC) is chronic cholestatic liver disease, which primarily affects young and middle aged men. PSC slowly damages bile duct by inflammation and scarring or fibrosis which eventually leads to blockage of bile ducts. PSC is autoimmune disease which can leads to cirrhosis which finally leads to liver failure. Particularly, men between the ages of 30 and 50 years, and being diagnosed with any inflammatory bowel disease (IBD) are likely to get primary sclerosing cholangitis (PSC).  

Increasing number of research and development activities combined with ongoing clinical trial studies on primary sclerosing cholangitis to understand its mechanisms and risk factors by various healthcare regulatory bodies and government agencies are some among the major factors expected to drive growth of the market. For instance, in September 2018, the U.S. Food and Drug Administration (FDA) awarded 12 new clinical trial research grants of more than US$ 18 million for next four year to enhance the development of medical products for patients with rare diseases. These research grants are awarded to principal investigators from academic institutions and industry across the U.S. 

Growing incidence of liver failure and bile cancer associated with PSC and future launch of PSC drugs which currently in clinical phase III are expected to offer lucrative growth opportunities in the near future.

The primary sclerosing cholangitis market has been segmented on the basis of drug, distribution channel, and region.

On the basis of drug, the primary sclerosing cholangitis market is segmented into BT1023, GS-9674, NGM282, OCA, LUM001, and others. On the basis of distribution channel, primary sclerosing cholangitis market segmented into hospitals, pharmacies, and retail pharmacies. 

On basis of region, the target market has been segmented into North America, Europe, Asia Pacific, Latin America, Middle East, and Africa.

Key players operating in the primary sclerosing cholangitis market includes Acorda Therapeutics, Inc., Gilead Sciences, Inc., NGM Biopharmaceuticals, Inc., Intercept Pharmaceuticals, Inc., Dr. Falk Pharma GmbH, Allergan Plc., Shire Plc., Durect Corporation, Conatus Pharmaceuticals, Inc., Sirnaomics, Inc., and Shenzhen HighTide Biopharmaceutical Ltd.

1. Research Objective and Assumption
   • Preface
   • Research Objectives
   • Study Scope
   • Years Considered for the study
   • Assumptions
   • Abbreviations
2. Research Methodology
   • Research data
   • Primary Data
     • Primary Interviews
     • Primary Breakdown
     • Key data from Primary Sources
     • Key Thickness Insights
   • Secondary Data
     • Major Secondary Sources
     • Secondary Sources
   • Market Estimation
   • Top-Down Approach
     • Approach for estimating Market Share by Top-Down Analysis (Supply Side)
   • Bottom-Up Approach
     • Approach for estimating market share by Bottom-up Analysis (Demand Side)
   • Market Breakdown and Data Triangulation
   • Research Assumptions
   • PORTER’s
   • Investment Outlook
3. Market Purview
   • Executive Summary
   • Key Findings—Global Outlook for Primary Sclerosing Cholangitis (PSC) Strategies
     • Key Questions this Study will Answer

     • By Drug (BT1023, GS-9674, NGM282, OCA, LUM001, and Others)

       By Distribution Channel (Hospital Pharmacy, and Retail Pharmacy)

       By Region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa)

   • Opportunity Map Analysis
   • Executive Summary—3 Big Predictions
4. Market Dynamics, Regulations, and Trends Analysis
   • Market Dynamics
     • Drivers
     • Restraints
     • Market Opportunities
     • Market Trends
   • DR Impact Analysis
   • PEST Analysis
   • Porter’s Five Forces Analysis
   • Opportunity Orbit
   • Overview
   • Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 – 2030
   • Y-o-Y Growth Analysis (%), 2020 – 2030
   • Regional Trends
   • Market Investment Feasibility Index
   • Macroeconomic Factor Analysis
5. Regional Analysis
   • Regional Revenue Analysis
   • Regional By segment Analysis
   • Reasons for regional growth
   • Key Player of particular region
   • Countries Include in the report:

1. • • North America (U.S., Canada)
     • Europe (UK, France, Germany, Russia, Italy, Rest of Europe)
     • Asia Pacific (India, Japan, South Korea, China, Rest of Asia Pacific)
     • Latin America (Brazil, Mexico, Rest of Latin America)
     • Middle East & Africa (GCC, Israel, South Africa, Rest of Middle East)

1. Competitive Landscape
   • Heat Map Analysis
   • Market Presence and Specificity Analysis
   • Competitive Overview
   • Competitive Benchmarking
   • Market Share Analysis
   • Key Developments In The Global Primary Sclerosing Cholangitis (PSC) Market
   • Key Developments: Mergers & Acquisitions
   • Key Developments: Collaboration
   • Key Developments: Contracts & Agreements
   • Key Developments: Expansion
   • Key Developments: Product Developments
2. Company Profiles

• Company Overview
• Product Portfolio
• Key Highlights
• Financial Performance
• Business Strategies
• SWOT Analysis

• • Acorda Therapeutics, Inc.

  • Gilead Sciences, Inc.

  • NGM Biopharmaceuticals, Inc.

  • Intercept Pharmaceuticals, Inc.

  • Dr. Falk Pharma GmbH

  • Allergan Plc.

  • Shire Plc.

  • Durect Corporation

  • Conatus Pharmaceuticals, Inc.

  • Sirnaomics, Inc.

  • Shenzhen HighTide Biopharmaceutical Ltd.

1. The Last Word
   • Future Impact
   • About Us
   • Contact